Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M31358 | [Leu15]-Gastrin I (human) | [Leu15]-Gastrin I (human) is a peptide that acts via cholecystokinin (CCK) or CCK-B receptor (CCK-BR). |
| M31109 | Gastrin I (rat) TFA | Gastrin I (rat) TFA is a peptide hormone, which can stimulate gastric acid secretion potently. |
| M9320 | Gastrin-I (human) | Gastrin-I (human) is the endogenous peptide produced in the stomach, which increases gastric acid secretion via cholecystokinin 2 (CCK2) receptor. |
| M9311 | Lorglumide sodium salt | Lorglumide (CR-1409) sodium salt is a potent cholecystokinin (CCK) receptor antagonist. |
| M7327 | SR 27897 | SR 27897 is a potent and selective CCK 1 antagonist. |
| M3274 | Pentagastrin | Pentagastrin (ICI-50123) is a synthetic polypeptide that has effects like gastrin when given parenterally. |
| M54219 | Sincalide | Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. |
| M54206 | Gastrin I, rat | Gastrin I, rat (Rat Gastrin-17) is a peptide hormone, can stimulate gastric acid secretion potently. |
| M54020 | Tetragastrin | Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. |
| M53910 | A71623 | A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. |
| M53222 | N-acetyl CCK-(26-30) amide | N-acetyl CCK-(26-30) amide (CCK-(26-30) (sulfated)) is a cholecystokinin (CCK) receptor antagonist. |
| M41796 | PD 135158 | PD 135158 (CAM 1028) is a selective CCKB receptor antagonist with an IC50 of 2.8 nM against mouse cortex CCKB. |
| M31025 | Mini Gastrin I, human TFA | Mini Gastrin I, human (TFA) is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide. |
| M30273 | Mini Gastrin I, human | Mini Gastrin I, human is a shorter version of human gastrin, consists of amino acids 5-17 of the parent peptide. |
| M29195 | Nastorazepide | Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Target：CCK-2 in vitro: Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. Check for active clinical trials or closed clinical trials using this agent. in vivo: Z-360 is a novel orally active CCK-2/gastrin receptor antagonist, significantly inhibits the growth of subcutaneous xenografts of human pancreatic tumor cells in mice, and that Z-360 combined with gemcitabine prolonged survival in a pancreatic carcinoma orthotopic xenograft mice. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
